DANBURY, Conn., Aug. 22 /PRNewswire-FirstCall/ -- Biodel, Inc. (Nasdaq: BIOD) today announced the addition of Ralf Rosskamp, M.D., to its Scientific Advisory Board (SAB).
Dr. Rosskamp was previously the Executive Vice President of Research and Development at Kos Pharmaceuticals, where he managed all research and development activities until Kos was acquired by Abbott Laboratories. Dr. Rosskamp's accomplishments at Kos include building an integrated research and development organization, globally expanding Kos's clinical research organization and assisting in the approval of four supplemental new drug applications.
"We are extremely honored to have Dr. Rosskamp join our SAB," said Dr. Solomon Steiner, CEO and Chairman of Biodel. "Dr. Rosskamp played an integral role in bringing insulin analogs to the market. His wealth of knowledge and clinical experience in the field of endocrinology will significantly contribute to the development of VIAject(TM), VIAtab(TM) and our two osteoporosis product candidates."
"I am delighted to join Biodel's SAB, especially at such an exciting time for the Company," said Dr. Rosskamp. "Biodel has created an innovative, injectable human insulin for diabetics and has made great progress in the clinical development of VIAject(TM). I look forward to collaborating with the Biodel team in their efforts to bring safer and more effective treatments to the diabetic patient population."
Prior to joining Kos, Dr. Rosskamp held prominent positions for thirteen years at Aventis Pharmaceuticals, a lead-developer of endocrinology products. At Aventis, Dr. Rosskamp was responsible for achieving FDA/EMEA approval of Lantus(R), the best-selling basal insulin analog and coordinating the clinical trials for Apidra(R), a rapid-acting insulin analog. In addition, Dr. Rosskamp managed the approval process for Actonel(R) Once-a-Week, which prevents and treats post-menopausal osteoporosis, and aided in completing the Phase III study program for Inhaled Insulin in collaboration with Pfizer.
Dr. Rosskamp is the author of over 20 publications in peer-reviewed journals and has published more than 50 abstracts. Dr. Rosskamp received his M.D. from the University of Bonn in 1978.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
|SOURCE Biodel, Inc.|
Copyright©2007 PR Newswire.
All rights reserved